|
May 17, 2022
|
AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
|
|
|
May 09, 2022
|
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
|
|
|
Apr 28, 2022
|
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
|
|
|
Apr 27, 2022
|
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
|
|
|
Apr 08, 2022
|
AC Immune Reports Changes to Senior Management
|
|
|
Mar 30, 2022
|
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
|
|
|
Mar 22, 2022
|
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
|
|
|
Mar 21, 2022
|
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
|
|
|
Mar 16, 2022
|
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
|
|
|
Feb 28, 2022
|
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
|
|